Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2656-2662

  Janjigian, Y Y ^a   Werner, D ^b   Pauligk, C ^b   Steinmetz, K ^b   Kelsen, D P ^a   Jager E ^b   Altmannsberger, H M ^b   Robinson, E ^c   Tafe, L J ^c   Tang, L H ^c   Shah, M A ^a   Al Batran, S E ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b KRANKENHAUS NORDWEST   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Esophagogastric cancer; Gastric cancer; Gastroesophageal cancer; Human epidermal growth factor receptor 2 (HER2)

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COHORT ANALYSIS; CONTINUOUS INFUSION; ESOPHAGUS CANCER; ETHNIC GROUP; EUROPE; FEMALE; HAZARD RATIO; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERNATIONAL COOPERATION; INTESTINE HISTOLOGY; LIVER METASTASIS; LOWER ESOPHAGUS SPHINCTER CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; TISSUE LEVEL; TREATMENT OUTCOME; TUMOR BIOPSY; UNITED STATES;

EID: 84867131579     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds104     Document Type: Article

References (55)

1. Slamon DJ, Clark GM, Wong SG. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
2. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
3. Seshadri R, Firgaira F, Horsfall D et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11: 1936-1942.
4. Dawood S, Broglio K, Buzdar AU et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28: 92-98.
5. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697.
6. Schuell B, Gruenberger T, Scheithauer W et al. HER 2/neu protein expression in colorectal cancer. BMC Cancer 2006;6: 123.
7. Eltze E, Wülfing C, Von Struensee D et al. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol 2005; 26: 1525-1531.
8. McKenzie SJ, DeSombre KA, Bast BS et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185(neu) in human ovarian cancer. Cancer 1993; 71: 3942-3946.
9. Hetzel DJ, Wilson TO, Keeney GL et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992; 47: 179-185.
10. Hirashima N, Takahashi W, Yoshii S et al. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 2001; 14: 556-562.
11. Mitra AB, Murty VVVS, Pratap M et al. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994; 54: 637-639.
12. Beckhardt RN, Kiyokawa N, Xi L et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995; 121: 1265-1270.
13. Orita H, Maehara Y, Emi Y et al. c-erbB-2 expression is predictive for lymphatic spread of clinical gastric carcinoma. Hepatogastroenterology 1997; 44: 294-298.
14. Yonemura Y, Ninomiya I, Yamaguchi A et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51: 1034-1038.
15. Tanner M, Hollmén M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-278.
16. Begnami MD, Fukuda E, Fregnani JHTG et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011; 29: 3030-3036
17. Allgayer H, Babic R, Gruetzner KU et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumorassociated protease systems. J Clin Oncol 2000; 18: 2201-2209.
18. Park DI, Yun JW, Park JH et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-1379.
19. Albino AP, Jaehne J, Altorki N et al. Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. Eur J Surg Oncol 1995; 21: 56-60.
20. Nakajima M, Sawada H, Yamada Y et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-1902.
21. Uchino S, Tsuda H, Maruyama K et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993; 72: 3179-3184.
22. García I, Vizoso F, Martín A et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003; 10: 234-241.
23. Mizutani T, Onda M, Tokunaga A et al. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993; 72: 2083-2088.
24. Takehana T, Kunitomo K, Kono K et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833-837.
25. Chariyalertsak S, Sugano K, Ohkura H et al. Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumor Biol 1994; 15: 294-303.
26. Sasano H, Date F, Imatani A et al. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993; 24: 584-589.
27. Tateishi M, Toda T, Minamisono Y et al. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 1992; 49: 209-212.
28. Yoon QSHH, Sukov WR, Wiktor AE et al. HER2 expression/amplification: frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). J Clin Oncol 2011; 29 (Suppl): (Abstr 4012).
29. Webb A, Scott-Mackie P, Cunningham D et al. The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. Eur J Cancer 1996; 32: 63-68.
30. Grabsch H, Sivakumar S, Gray S et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65.
31. Marx AH, Tharun L, Muth J et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009; 40: 769-777.
32. Terashima MAO, Kitada K, Ichikawa W et al. Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study. J Clin Oncol 2011; 29 (Suppl): (Abstr 4013).
33. Thompson S, Sullivan T, Davies R et al. HER-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 2011; 18: 2010-2017.
34. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
35. Rüschoff J, Dietel M, Baretton G et al. HER2 diagnostics in gastric cancer- guideline validation and development of standardized immunohistochemical testing. Virchows Archiv 2010; 457: 299-307.
36. Al-Batran SE, Hartmann JT, Hofheinz R et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008; 19: 1882-1887.
37. Al-Batran S, Ho-mann N, Hartmann JT et al. 5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2010; 28 (Suppl): 15s (Abstr 4013).
38. Al-Batran S, Hofheinz R, Homann N et al. Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2011; 29 (Suppl): (Abstr 4070).
39. Shah MA, Shibata S, Stoller RG et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). J Clin Oncol (Meeting Abstracts) 2010; 28 (Suppl 15): (Abstr 4014).
40. Shah MA, Jhawer M, Ilson DH et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011; 29: 868-874.
41. Al-Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442.
42. Sakai K, Mori S, Kawamoto T. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986; 77: 1047-1052.
43. Houldsworth J, Cordon-Cardo C, Ladanyi M et al. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990; 50: 6417-6422.
44. Kunz PL, Mojtahed A, Fisher GA et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012; 20: 13-24.
45. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New Engl J Med 2007; 357: 1810-1820.
46. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-1553.
47. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
48. Langer R, Von Rahden BHA, Nahrig J et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 2006; 59: 631-634.
49. Rauser S, Weis R, Braselmann H et al. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res 2007; 13: 5115-5123.
50. Reichelt U, Duesedau P, Tsourlakis MC et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2006; 20: 120-129.
51. Park YSMR, Park HJ, Kim HJ et al. HER2 status as an independent prognostic marker in patients with advanced gastric cancer receiving adjuvant chemotherapy after curative gastrectomy. J Clin Oncol (Meeting Abstracts) 2011; 29 (Suppl 15): (Abstr 4084).
52. Tafe LJ, Janjigian YY, Zaidinski M et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 2011; 135: 1460-1465.
53. Mayer B, Johnson JP, Leitl F et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 1993; 53: 1690-1695.
54. Machado JC, Carneiro F, Sobrinho-Simões M et al. E-cadherin mutations in gastric carcinoma [1] (multiple letters). J Pathol 2000; 191: 466-468.
55. Huntsman DG, Carneiro F, Lewis FR et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001; 344: 1904-1909.